Murine studies have demonstrated the potential of RhoB restoration to suppress ovarian cancer xenografts and the chemotherapeutic agent gemcitabine has been shown to act on miR-19a, potentially inhibiting tumor growth by means of RHOB [83,84,85,107,108]. The gene discussed is RHOB; the disease is ovarian cancer.